Candel Therapeutics Announces It Expects to Report Topline D

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Sylvia Wheeler , Aljanae Reynolds , Candel Therapeutics Inc , Drug Administration , Company Nasdaq , Therapeutics Announces It Expects , Report Topline Data , Non Small Cell Lung Cancer , Second Quarter , Paul Peter Tak , Chief Executive Officer , Clin Oncol , Fast Track , Discovery Platform , Private Securities Litigation Reform Act , Quarterly Report , Life Science ,